CANSINOBIO's Recombinant Polio Vaccine Secures Clinical Trial Approval in China

Stock News

Jul 16, 2025

CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate clinical trials. This vaccine, crafted through sophisticated protein structure design and virus-like particle (VLP) assembly technology, eliminates viral genetic material entirely and operates independently of live viruses during both production and testing phases. Such features are anticipated to deliver exceptional safety and robust immunogenicity. Notably, the non-infectious VLP-based polio vaccine stands endorsed by the World Health Organization as a premier choice for future polio eradication efforts, positioning it as a potentially ideal solution for the disease's global elimination.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1149694080"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149694080\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149694080?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149694080","market":"sg","top_or_hot":-1,"title":"CANSINOBIO's Recombinant Polio Vaccine Secures Clinical Trial Approval in China","media":"Stock News","content":"<p>CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate clinical trials. This vaccine, crafted through sophisticated protein structure design and virus-like particle (VLP) assembly technology, eliminates viral genetic material entirely and operates independently of live viruses during both production and testing phases. Such features are anticipated to deliver exceptional safety and robust immunogenicity. Notably, the non-infectious VLP-based polio vaccine stands endorsed by the World Health Organization as a premier choice for future polio eradication efforts, positioning it as a potentially ideal solution for the disease's global elimination.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO's Recombinant Polio Vaccine Secures Clinical Trial Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO's Recombinant Polio Vaccine Secures Clinical Trial Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-07-16 17:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate clinical trials. This vaccine, crafted through sophisticated protein structure design and virus-like particle (VLP) assembly technology, eliminates viral genetic material entirely and operates independently of live viruses during both production and testing phases. Such features are anticipated to deliver exceptional safety and robust immunogenicity. Notably, the non-infectious VLP-based polio vaccine stands endorsed by the World Health Organization as a premier choice for future polio eradication efforts, positioning it as a potentially ideal solution for the disease's global elimination.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1149694080","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149694080","pubTimestamp":1752657100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","03347":"泰格医药","BK1576":"医药外包概念","06185":"康希诺生物","BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"康希诺生物重组脊髓灰质炎疫苗在中国获得临床试验批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"03347":1,"06185":1},"content_text":"CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate clinical trials. This vaccine, crafted through sophisticated protein structure design and virus-like particle (VLP) assembly technology, eliminates viral genetic material entirely and operates independently of live viruses during both production and testing phases. Such features are anticipated to deliver exceptional safety and robust immunogenicity. Notably, the non-infectious VLP-based polio vaccine stands endorsed by the World Health Organization as a premier choice for future polio eradication efforts, positioning it as a potentially ideal solution for the disease's global elimination.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}